| Your Current Location : Fund Card : Portfolio Classification |
 |
|
|
| |
| Bajaj Finserv Healthcare Fund (G) Direct |
| [Equity: Sectoral] |
|
| |
|
|
| Instruments Breakdown |
| Instruments |
Composition |
| Current Asset |
0.61 |
| Derivatives/Mutual Fund/ETF |
1.30 |
| Equity |
95.97 |
| Trep |
2.12 |
|
| |
| Concentration Analysis |
| Top 5 Holdings |
38.47% |
| Top 10 Holdings |
60.80% |
| Top 25 Holdings |
90.99% |
|
|
|
| |
| Sector Analysis |
| Sector/Ratings |
Net Asset(%) |
| Pharma & Biotech |
71.29 |
| Healthcare |
16.96 |
| Cash |
2.73 |
| Food Beverage & Tobacco |
2.27 |
| Consumer Durables |
2.0 |
| Debt MF |
1.3 |
| Chemicals |
1.2 |
| Technology |
0.92 |
| Miscellaneous |
0.82 |
| Electricals |
0.26 |
| Fertilisers |
0.25 |
|
|
|
|
|
| Portfolio Metrics |
|
| PB Ratio |
6.35 |
| PE Ratio |
51.44 |
|
| |
| Top 25 Holdings |
|
|
| Holdings |
Net Asset(%) |
| Divis Laboratories Ltd. |
10.55 |
| Sun Pharmaceutical Industries Ltd. |
8.21 |
| RUBICON RESEARCH LIMITED |
6.81 |
| PIRAMAL PHARMA LIMITED |
6.72 |
| Aurobindo Pharma Ltd. |
6.18 |
| Apollo Hospitals Enterprises Ltd. |
6.00 |
| Torrent Pharmaceuticals Ltd. |
5.03 |
| Neuland Laboratories Limited. |
4.11 |
| Emcure Pharmaceuticals Limited |
3.84 |
| Max Healthcare Institute Limited |
3.35 |
| Fortis Healthcare Ltd |
2.69 |
| Zydus Lifesciences Limited |
2.56 |
| Ipca Laboratories Ltd. |
2.46 |
| Laurus Labs Limited |
2.36 |
| Vijaya Diagnostic Centre Limited |
2.31 |
| Zydus Wellness Limited |
2.27 |
| SENORES PHARMACEUTICALS LIMITED |
2.15 |
| Clearing Corporation of India Ltd |
2.12 |
| Shaily Engineering Plastics Ltd. |
2.00 |
| GlaxoSmithkline Pharmaceuticals Ltd. |
1.79 |
| Glenmark Pharmaceuticals ltd |
1.70 |
| Dr. Lal Pathlabs Limited |
1.68 |
| Sanofi Consumer Healthcare India Limited |
1.41 |
| Cipla Ltd. |
1.39 |
| Bajaj Finserv Money Market Fund-Direct Plan-Growth |
1.30 |
|
|
|
| |
|
| |
| Sector Analysis Graphical Mode |
|
| |
|
|
| |
|
 |
| |
|
|
|
